UroGen Pharma Ltd
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About UroGen Pharma Ltd
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
/ 
Frequently asked questions
To buy UroGen Pharma Ltd stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for UroGen Pharma Ltd by name or ticker, choose the number of shares, and place your order.
The ticker symbol for UroGen Pharma Ltd is URGN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
UroGen Pharma Ltd has its primary listing on NASDAQ. You can trade UroGen Pharma Ltd with a Saxo account, alongside thousands of other stocks worldwide.
Yes, UroGen Pharma Ltd is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include UroGen Pharma Ltd as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like UroGen Pharma Ltd.